Year |
Citation |
Score |
2023 |
Juric V, Mayes E, Binnewies M, Lee T, Canaday P, Pollack JL, Rudolph J, Du X, Liu VM, Dash S, Palmer R, Jahchan NS, Ramoth ÅJ, Lacayo S, Mankikar S, et al. TREM1 activation of myeloid cells promotes antitumor immunity. Science Translational Medicine. 15: eadd9990. PMID 37647386 DOI: 10.1126/scitranslmed.add9990 |
0.306 |
|
2023 |
Turan T, Kongpachith S, Halliwill K, McLaughlin RT, Binnewies M, Reddy D, Zhao X, Mathew R, Ye S, Jacob HJ, Samayoa J. iBRIDGE: A Data Integration Method to Identify Inflamed Tumors from Single-Cell RNAseq Data and Differentiate Cell Type-Specific Markers of Immune-Cell Infiltration. Cancer Immunology Research. PMID 37023414 DOI: 10.1158/2326-6066.CIR-22-0283 |
0.313 |
|
2019 |
Jahchan NS, Mujal AM, Pollack JL, Binnewies M, Sriram V, Reyno L, Krummel MF. Tuning the Tumor Myeloid Microenvironment to Fight Cancer. Frontiers in Immunology. 10: 1611. PMID 31402908 DOI: 10.3389/Fimmu.2019.01611 |
0.391 |
|
2019 |
Dodagatta-Marri E, Meyer DS, Reeves MQ, Paniagua R, To MD, Binnewies M, Broz ML, Mori H, Wu D, Adoumie M, Del Rosario R, Li O, Buchmann T, Liang B, Malato J, et al. α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas. Journal For Immunotherapy of Cancer. 7: 62. PMID 30832732 DOI: 10.1186/S40425-018-0493-9 |
0.344 |
|
2019 |
Juric V, Chan C, Mayes E, Norng M, Le T, Dash S, Sriram V, Lu E, Pollack JL, Binnewies M, Waszczuk J, Du X, Mankikar S, Pal A, Baker KP, et al. Abstract C105: Targeting of TREM1+ myeloid cells to promote antitumor immunity Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C105 |
0.381 |
|
2019 |
Binnewies M, Abushawish M, Lee T, Le T, Pollack JL, Lu E, Chen A, Mehta R, Jahchan N, Huang V, Du X, Dash S, Norng M, Pal A, Baker KP, et al. Abstract C104: Therapeutic targeting of TREM2+ tumor-associated macrophages as a means of overcoming checkpoint inhibitor resistance Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C104 |
0.302 |
|
2018 |
Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, Alvarado MD, Wolf DM, Bogunovic D, Bhardwaj N, Daud AI, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nature Medicine. PMID 29942093 DOI: 10.1038/S41591-018-0085-8 |
0.415 |
|
2018 |
Mujal A, Barry K, Roberts E, Binnewies M, Ruhland M, Chan V, Krummel MF. Abstract IA05: Imaging- and single cell- based insights into the antitumor immune responses Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-Ia05 |
0.325 |
|
2017 |
Hérault A, Binnewies M, Leong S, Calero-Nieto FJ, Zhang SY, Kang YA, Wang X, Pietras EM, Chu SH, Barry-Holson K, Armstrong S, Göttgens B, Passegué E. Myeloid progenitor cluster formation drives emergency and leukaemic myelopoiesis. Nature. PMID 28355185 DOI: 10.1038/Nature21693 |
0.751 |
|
2016 |
Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, Kaisho T, Bogunovic D, Bhardwaj N, Krummel MF. Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. Cancer Cell. PMID 27424807 DOI: 10.1016/J.Ccell.2016.06.003 |
0.346 |
|
2016 |
Herault A, Binnewies M, Leong S, Calero F, Zhang SY, Pietras E, Chu H, Barry-Holson K, Armstrong S, Göttgens B, Passegue E. Myeloid progenitor cluster formation drives regenerative and leukemic myelopoiesis Experimental Hematology. 44: S79-S80. DOI: 10.1016/J.Exphem.2016.06.157 |
0.686 |
|
2015 |
Broz M, Binnewies M, Boldajipour B, Nelson A, Pollock J, Erle D, Barczak A, Rosenblum M, Daud A, Barber D, Amigorena S, Veer LJv', Sperling A, Wolf D, Krummel MF. Abstract B65: Dissecting the tumor myeloid compartment reveals rare activating antigen presenting cells, critical for T cell immunity Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-B65 |
0.354 |
|
2014 |
Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, Amigorena S, Van't Veer LJ, Sperling AI, Wolf DM, Krummel MF. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 26: 638-52. PMID 25446897 DOI: 10.1016/J.Ccell.2014.09.007 |
0.384 |
|
2014 |
Pietras EM, Lakshminarasimhan R, Techner JM, Fong S, Flach J, Binnewies M, Passegué E. Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons. The Journal of Experimental Medicine. 211: 245-62. PMID 24493802 DOI: 10.1084/Jem.20131043 |
0.724 |
|
2013 |
Schepers K, Pietras EM, Reynaud D, Flach J, Binnewies M, Garg T, Wagers AJ, Hsiao EC, Passegué E. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell. 13: 285-99. PMID 23850243 DOI: 10.1016/J.Stem.2013.06.009 |
0.655 |
|
2013 |
Li M, Jones L, Gaillard C, Binnewies M, Ochoa R, Garcia E, Lam V, Wei G, Yang W, Lobe C, Hermiston M, Passegué E, Kogan SC. Initially disadvantaged, TEL-AML1 cells expand and initiate leukemia in response to irradiation and cooperating mutations. Leukemia. 27: 1570-3. PMID 23443342 DOI: 10.1038/Leu.2013.15 |
0.601 |
|
2013 |
Warr MR, Binnewies M, Flach J, Reynaud D, Garg T, Malhotra R, Debnath J, Passegué E. FOXO3A directs a protective autophagy program in haematopoietic stem cells. Nature. 494: 323-7. PMID 23389440 DOI: 10.1038/Nature11895 |
0.653 |
|
2011 |
Reynaud D, Pietras E, Barry-Holson K, Mir A, Binnewies M, Jeanne M, Sala-Torra O, Radich JP, Passegué E. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell. 20: 661-73. PMID 22094259 DOI: 10.1016/J.Ccr.2011.10.012 |
0.738 |
|
Show low-probability matches. |